RxDoctor Payments Data

Bhaskara Ganti, MD

Pain Medicine · Austin, TXNPI 1477917292

Payments from drug & device makers

$18,372in general payments, 2019–2025

Across 570 payments — averaging $32.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$11K
  • Medtronic$3K
  • Nevro Corp.$1K
  • Relievant Medsystems, Inc.$1K
  • Boston Scientific$613
  • Spinal Simplicity, LLC$413
  • plus $1K from 11 others

What the payments were for

  • Travel & lodging$1881%
  • Food & beverage$18,18499%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$18,372 in reported general payments places this provider in the 85th percentile of 583 pain medicine providers in Texas.

See all pain medicine providers in Texas

Medicare billing

Part B allowed, 2024
$264,064
Medicare patients
316
Services billed
3,941

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen1,905$51,892
Buprenorphine77$15,220
BelbucaBuprenorphine Hcl23$12,711
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl112$9,404
Gabapentin580$6,813
Xtampza ErOxycodone Myristate12$6,214
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen289$6,058
Lidocaine63$5,911
Pregabalin301$5,121
OxycontinOxycodone Hcl14$4,062
Oxycodone Hcl252$3,632
Hydrocodone-IbuprofenHydrocodone/Ibuprofen22$3,274
Tramadol Hcl318$2,428
Tizanidine Hcl148$2,209
Morphine Sulfate ErMorphine Sulfate72$2,101

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Belbuca, Xtampza Er$80$18,92435 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 583 pain medicine providers in Texas.

Other pain medicine in Austin

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →